Theravance Biopharma Inc (TBPH):企業の財務・戦略的SWOT分析

◆英語タイトル:Theravance Biopharma Inc (TBPH) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1326
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,125見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,250見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥39,375見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Theravance Biopharma Inc (TBPH) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Theravance Biopharma Inc (Theravance Biopharma) is a diversified biopharmaceutical company that focuses on the discovery, development, and marketing of organ-selective medicines for the treatment of inflammation and immune system disorders. The company is investigating its pipeline candidates for the treatment of asthma; neurogenic orthostatic hypotension (nOH); gastrointestinal motility disorders; ulcerative colitis; heart failure; chronic kidney disease (CKD); Crohn’s disease; gastroparesis and concurrent bacteremia. Its Yupelritm (revefenacin) obtained the US FDA approval for the treatment of chronic obstructive pulmonary disease (COPD) and is available in the US. The company has subsidiaries in the US, Ireland and the UK. Theravance Biopharma is headquartered in South San Francisco, California, the US.

Theravance Biopharma Inc Key Recent Developments

Dec 31,2019: Theravance Biopharma and Pfizer enter global license agreement for skin-targeted, locally-acting pan-Janus Kinase (JAK) inhibitor program
Dec 24,2019: Theravance Biopharma reports fourth quarter and full-year 2019 financial results and provides business update
Nov 05,2019: Theravance Biopharma reports third quarter 2019 financial results and provides business update
Jul 31,2019: Theravance Biopharma reports second quarter 2019 financial results and provides business update
Jun 21,2019: Recursion names Theravance veteran as CSO

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Theravance Biopharma Inc – Key Facts
Theravance Biopharma Inc – Key Employees
Theravance Biopharma Inc – Key Employee Biographies
Theravance Biopharma Inc – Major Products and Services
Theravance Biopharma Inc – History
Theravance Biopharma Inc – Company Statement
Theravance Biopharma Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Theravance Biopharma Inc – Business Description
Theravance Biopharma Inc – Corporate Strategy
Theravance Biopharma Inc – SWOT Analysis
SWOT Analysis – Overview
Theravance Biopharma Inc – Strengths
Theravance Biopharma Inc – Weaknesses
Theravance Biopharma Inc – Opportunities
Theravance Biopharma Inc – Threats
Theravance Biopharma Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Theravance Biopharma Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Dec 24, 2019: Theravance Biopharma reports fourth quarter and full-year 2019 financial results and provides business update
Nov 05, 2019: Theravance Biopharma reports third quarter 2019 financial results and provides business update
Jul 31, 2019: Theravance Biopharma reports second quarter 2019 financial results and provides business update
Jun 17, 2019: Theravance and Mylan expand agreement for nebulised revefenacin
May 07, 2019: Theravance Biopharma announces first quarter 2019 financial results
Feb 26, 2019: Theravance Biopharma announces fourth quarter and full year 2018 financial results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Theravance Biopharma Inc, Key Facts
Theravance Biopharma Inc, Key Employees
Theravance Biopharma Inc, Key Employee Biographies
Theravance Biopharma Inc, Major Products and Services
Theravance Biopharma Inc, History
Theravance Biopharma Inc, Subsidiaries
Theravance Biopharma Inc, Key Competitors
Theravance Biopharma Inc, Ratios based on current share price
Theravance Biopharma Inc, Annual Ratios
Theravance Biopharma Inc, Annual Ratios (Cont...1)
Theravance Biopharma Inc, Interim Ratios
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Theravance Biopharma Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Theravance Biopharma Inc, Performance Chart (2015 - 2019)
Theravance Biopharma Inc, Ratio Charts
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Theravance Biopharma Inc (TBPH):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mitochon Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Mitochon Pharmaceuticals Inc (Mitochon Pharma) is a biotechnology company that develops drugs for neurodegenerative and neuromuscular diseases. The company’s pipeline products include mitochondrial modulators such as MP-101, MP-201 and MP-301. It targets diseases such as batten disease, stro …
  • Sahara Petrochemicals Co:企業の戦略的SWOT分析
    Sahara Petrochemicals Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Tadano Ltd:企業の戦略・SWOT・財務情報
    Tadano Ltd - Strategy, SWOT and Corporate Finance Report Summary Tadano Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Rubis SCA (RUI):企業の財務・戦略的SWOT分析
    Rubis SCA (RUI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Stratatech Corp:製品パイプライン分析
    Summary Stratatech Corp (Stratatech), a subsidiary of Mallinckrodt Plc is a healthcare products provider that offers skin regeneration therapies. The company’s products include StrataGraft skin tissue, a temporary wound cover that promotes wound healing and ExpressGraft skin tissue, a genetically en …
  • Baltimore Gas and Electric Co:企業の発電所・SWOT分析2018
    Baltimore Gas and Electric Co - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Yoshinoya Holdings Co Ltd
    Yoshinoya Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Yoshinoya Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Tatry Mountain Resorts, AS:戦略・SWOT・企業財務分析
    Tatry Mountain Resorts, AS - Strategy, SWOT and Corporate Finance Report Summary Tatry Mountain Resorts, AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Martin Marietta Materials, Inc.:戦略・SWOT・企業財務分析
    Martin Marietta Materials, Inc. - Strategy, SWOT and Corporate Finance Report Summary Martin Marietta Materials, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Cerner Corp (CERN)-医療機器分野:企業M&A・提携分析
    Summary Cerner Corp (Cerner) is a provider of healthcare information technology and related services. It offers a comprehensive range of solutions and services which assist the clinical, financial and operational needs of organizations. The company’s major solutions include extended care solutions; …
  • Keryx Biopharmaceuticals Inc (KERX)-製薬・医療分野:企業M&A・提携分析
    Summary Keryx Biopharmaceuticals Inc (Keryx) develops and commercializes new therapies for the treatment of renal disease. The company’s lead product Auryxia (ferric citrate) is an FDA approved oral, absorbable iron-based phosphate binder, which helps lower the amount of phosphate in human blood. Au …
  • AC Immune SA (ACIU):医療機器:M&Aディール及び事業提携情報
    Summary AC Immune SA (AC Immune) is a biopharmaceutical company that develops products for treating neurodegenerative diseases. It discovers, designs and develops innovative proprietary medicines to prevent, diagnose and treat neurodegenerative diseases associated with protein misfolding. The compan …
  • Tong Yang Life Insurance Co., Ltd.:企業の戦略・SWOT・財務分析
    Tong Yang Life Insurance Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Tong Yang Life Insurance Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Albemarle Corporation:企業の戦略・SWOT・財務情報
    Albemarle Corporation - Strategy, SWOT and Corporate Finance Report Summary Albemarle Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Petro Matad Ltd (MATD):企業の財務・戦略的SWOT分析
    Summary Petro Matad Ltd (Petro Matad) is an oil and gas company that develops and operates oil and gas exploration properties. The company’s upstream oil and gas exploration asset base includes Block IV, Block XX, and Block V. Its Block XX is located in the far eastern part of Mongolia producing oil …
  • Reliance Capital Ltd:企業の戦略・SWOT・財務分析
    Reliance Capital Ltd - Strategy, SWOT and Corporate Finance Report Summary Reliance Capital Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • KT Corporation:企業のM&A・事業提携・投資動向
    KT Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's KT Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Solaris d.d.:企業の戦略・SWOT・財務情報
    Solaris d.d. - Strategy, SWOT and Corporate Finance Report Summary Solaris d.d. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • RKW SE:企業の戦略的SWOT分析
    RKW SE - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Hon Hai Precision Industry Co., Ltd.:企業のM&A・事業提携・投資動向
    Hon Hai Precision Industry Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Hon Hai Precision Industry Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆